ArticleNeurosurgery2020
Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multi-Institutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF).
Article in Neurosurgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Brain metastases from small cell lung cancer: focal therapies improve outcomes in the contemporary era.Journal of neuro-oncology · 2025Article
- Treatment and survival of patients with small cell lung cancer and brain metastasis.Journal of neuro-oncology · 2023Article
- Review
- Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE).Journal of the National Cancer Institute · 2023Article
- Article
- Prediction of treatment response in patients with brain metastasis receiving stereotactic radiosurgery based on pre-treatment multimodal MRI radiomics and clinical risk factors: A machine learning model.Frontiers in oncology · 2023Article
- Analysis of Key Clinical Variables and Radiological Manifestations Associated with the Treatment Response of Patients with Brain Metastases to Stereotactic Radiosurgery.Journal of clinical medicine · 2022Article
- Review
- Management Strategies for Large Brain Metastases.Frontiers in oncology · 2022Review
- Benefits of Prophylactic Cranial Irradiation in the MRI Era for Patients With Limited Stage Small Cell Lung Cancer.Frontiers in oncology · 2022Article
- Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.Journal of thoracic disease · 2021Review
- Radiosurgery for small-cell lung cancer brain metastases: a review.Journal of thoracic disease · 2020Review
- Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer.Journal of thoracic disease · 2020Review
- Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.JAMA oncology · 2020Article
- Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy.Journal of radiosurgery and SBRT · 2020Article
- Stereotactic Radiosurgery for Brain Metastases in Patients With Small Cell Lung Cancer.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 4 countries.
Funding
Abstract
backgroundDespite a high incidence of brain metastases in patients with small-cell lung cancer (SCLC), limited data exist on the use of stereotactic radiosurgery (SRS), specifically Gamma Knife™ radiosurgery (Elekta AB), for SCLC brain metastases.
objectiveTo provide a detailed analysis of SCLC patients treated with SRS, focusing on local failure, distant brain failure, and overall survival (OS).
methodsA multi-institutional retrospective review was performed on 293 patients undergoing SRS for SCLC brain metastases at 10 medical centers from 1991 to 2017. Data collection was performed according to individual institutional review boards, and analyses were performed using binary logistic regression, Cox-proportional hazard models, Kaplan-Meier survival analysis, and competing risks analysis.
resultsTwo hundred thirty-two (79%) patients received SRS as salvage following prior whole-brain irradiation (WBRT) or prophylactic cranial irradiation, with a median marginal dose of 18 Gy. At median follow-up after SRS of 6.4 and 18.0 mo for surviving patients, the 1-yr local failure, distant brain failure, and OS were 31%, 49%, and 28%. The interval between WBRT and SRS was predictive of improved OS for patients receiving SRS more than 1 yr after initial treatment (21%, <1 yr vs 36%, >1 yr, P = .01). On multivariate analysis, older age was the only significant predictor for OS (hazard ratio 1.63, 95% CI 1.16-2.29, P = .005).
conclusionSRS plays an important role in the management of brain metastases from SCLC, especially in salvage therapy following WBRT. Ongoing prospective trials will better assess the value of radiosurgery in the primary management of SCLC brain metastases and potentially challenge the standard application of WBRT in SCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.